Mechanistic insights toward progress in alogliptin beyond glycemic control: translational perspective

IF 2.5 Q2 MULTIDISCIPLINARY SCIENCES Beni-Suef University Journal of Basic and Applied Sciences Pub Date : 2025-02-05 DOI:10.1186/s43088-025-00601-5
Faraha Ahmed, Syed Sufian Ahmad, M. Mumtaz Alam, M. Shaqiquzzaman, Abul Kalam Najmi, Mohammad Ahmed Khan
{"title":"Mechanistic insights toward progress in alogliptin beyond glycemic control: translational perspective","authors":"Faraha Ahmed,&nbsp;Syed Sufian Ahmad,&nbsp;M. Mumtaz Alam,&nbsp;M. Shaqiquzzaman,&nbsp;Abul Kalam Najmi,&nbsp;Mohammad Ahmed Khan","doi":"10.1186/s43088-025-00601-5","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Alogliptin belongs to gliptin family of drugs that inhibits ubiquitous enzyme dipeptidyl peptidase-4 (DPP-4). Gliptins increase the life-span of incretin hormones that appear to benefit functioning of several organs via various signaling pathways.</p><h3>Main body</h3><p>Alogliptin is approved for treatment of type 2 diabetes mellitus (T2DM) in majority of the countries. It is administered orally and efficacious as monotherapy as well as combined therapy with other T2DM drugs, such as pioglitazone and metformin. It has a good safety profile, well-tolerated in elderly patients and in patients with co-morbid conditions including risks of cardiovascular event, renal or hepatic insufficiency. Therefore, alogliptin is incessantly experimented and investigated for its therapeutic benefit. Recent developments have indicated potential of alogliptin in discrete pathological conditions. Emerging evidences suggest prominent cardioprotective, hepatoprotective, reno-protective, anti-inflammatory and lipid-lowering capacity of alogliptin. Apart from inhibiting DPP-4 enzyme, alogliptin also affects several signaling mechanisms to exhibit protective effects in patients with diabetes-induced complications.</p><h3>Conclusion</h3><p>This review highlights the potential role of alogliptin and mechanisms involved in amelioration of several other pathological conditions apart from its role in glucose metabolism. Thus, this may provide insights for better utilization and repurposing of alogliptin as a therapeutic agent.</p></div>","PeriodicalId":481,"journal":{"name":"Beni-Suef University Journal of Basic and Applied Sciences","volume":"14 1","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjbas.springeropen.com/counter/pdf/10.1186/s43088-025-00601-5","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Beni-Suef University Journal of Basic and Applied Sciences","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1186/s43088-025-00601-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Alogliptin belongs to gliptin family of drugs that inhibits ubiquitous enzyme dipeptidyl peptidase-4 (DPP-4). Gliptins increase the life-span of incretin hormones that appear to benefit functioning of several organs via various signaling pathways.

Main body

Alogliptin is approved for treatment of type 2 diabetes mellitus (T2DM) in majority of the countries. It is administered orally and efficacious as monotherapy as well as combined therapy with other T2DM drugs, such as pioglitazone and metformin. It has a good safety profile, well-tolerated in elderly patients and in patients with co-morbid conditions including risks of cardiovascular event, renal or hepatic insufficiency. Therefore, alogliptin is incessantly experimented and investigated for its therapeutic benefit. Recent developments have indicated potential of alogliptin in discrete pathological conditions. Emerging evidences suggest prominent cardioprotective, hepatoprotective, reno-protective, anti-inflammatory and lipid-lowering capacity of alogliptin. Apart from inhibiting DPP-4 enzyme, alogliptin also affects several signaling mechanisms to exhibit protective effects in patients with diabetes-induced complications.

Conclusion

This review highlights the potential role of alogliptin and mechanisms involved in amelioration of several other pathological conditions apart from its role in glucose metabolism. Thus, this may provide insights for better utilization and repurposing of alogliptin as a therapeutic agent.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.60
自引率
0.00%
发文量
0
期刊介绍: Beni-Suef University Journal of Basic and Applied Sciences (BJBAS) is a peer-reviewed, open-access journal. This journal welcomes submissions of original research, literature reviews, and editorials in its respected fields of fundamental science, applied science (with a particular focus on the fields of applied nanotechnology and biotechnology), medical sciences, pharmaceutical sciences, and engineering. The multidisciplinary aspects of the journal encourage global collaboration between researchers in multiple fields and provide cross-disciplinary dissemination of findings.
期刊最新文献
Mitigation of cyclophosphamide-induced premature ovarian insufficiency in rats through bone marrow-derived mesenchymal stem cells and placental extract therapy: a comprehensive evaluation Mechanistic insights toward progress in alogliptin beyond glycemic control: translational perspective Exploring and detecting predictors associated with survival and mortality of cervical cancer patients: a 10-year retrospective study Discovering the anti-parasitic activity of melatonin loaded lecithin/chitosan nanoparticles against giardiasis and cryptosporidiosis in Balb/c infected mice Identification and genetic analysis of the recent Avian pox viruses from infected pigeons and chickens
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1